📰 Christopher Posner News
Page 3 - Christopher Posner News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Christopher Posner. Real-time updates on events, politics, business and more.
March 25, 2023
Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) shares passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $10.11 and traded as low as $4.85. Cara Therapeutics shares last traded at $4.92, with a volume of 486,751 shares. Analyst Ratings Changes Several […]
March 7, 2023
The market closed mixed, but these two companies gave investors some bad news.
December 4, 2022
24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm’s Board of Directors CELEBRATION, Fla., Nov. ...
November 30, 2022
24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm’s Board of Directors CELEBRATION, Fla., Nov. ...
August 24, 2022
24.08.2022 - Presentation will highlight opportunity for oral difelikefalin to address a significant unmet need in the treatment of pruritus in patients with NPSTAMFORD, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) - Cara Therapeutics, Inc. (Nasdaq: CARA), a ...
August 19, 2022
Kapruvia (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Therapy recently
August 19, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
August 19, 2022
Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated...
August 19, 2022
The Swiss Agency for Therapeutic Products (Swissmedic) has approved Cara Therapeutics’ (NASDAQ:CARA) lead candidate KORSUVA (difelikefalin) ...
May 11, 2022
Wall Street analysts expect Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) to report $15.33 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Cara Therapeutics’ earnings, with the lowest sales estimate coming in at $7.50 million and the highest estimate coming in at $22.28 million. The company […]